Evaxion to present preclinical proof-of-concept for ERV cancer vaccine concept

Evaxion Biotech (EVAX) will present preclinical Proof-of-Concept for its precision cancer vaccine concept, targeting non-conventional ERV tumor antigens shared across patients at the ESMO Immuno-Oncology Congress, taking place from December 11-13, 2024, in Geneva, Switzerland. The data to be presented stems from studies in human cells and mouse tumor models. The studies investigated human T-cell responses and mouse tumor growth inhibition induced by precision ERV vaccine targets identified using Evaxion’s AI-Immunology platform. AI-Immunology can select ERV antigens for precision therapeutic cancer vaccines, offering therapeutic options for multiple specific cancer types and potentially enabling treatment for patients who are unresponsive to conventional cancer immunotherapy. The new concept of deploying ERVs as vaccine targets allows for designing precision cancer vaccines that could be effective across diverse immune system characteristics, making them suitable for a wide range of patients. Evaxion plans to utilize this now preclinically validated concept to design new precision vaccine candidates to complement our existing pipeline of personalized cancer vaccines.